DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different?

Author:

Timbres Jasmine1,Kohut Kelly2,Caneppele Michele3,Troy Maria4,Schmidt Marjanka K.56ORCID,Roylance Rebecca7,Sawyer Elinor1ORCID

Affiliation:

1. Breast Cancer Genetics, King’s College London, London SE1 9RT, UK

2. St George’s University Hospitals NHS Foundation Trust, Blackshaw Rd, London SW17 0QT, UK

3. Excelya, 35 rue de Paris, 92100 Boulogne, France

4. Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK

5. Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

6. Department of Clinical Genetics, Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands

7. University College London Hospitals NHS Foundation Trust, 235 Euston Rd., London NW1 2BU, UK

Abstract

Ductal carcinoma in situ (DCIS) is widely accepted as a precursor of invasive ductal carcinoma (IDC). Lobular carcinoma in situ (LCIS) is considered a risk factor for invasive lobular carcinoma (ILC), and it is unclear whether LCIS is also a precursor. Therefore, it would be expected that similar risk factors predispose to both DCIS and IDC, but not necessarily LCIS and ILC. This study examined associations with risk factors using data from 3075 DCIS cases, 338 LCIS cases, and 1584 controls aged 35–60, recruited from the UK-based GLACIER and ICICLE case-control studies between 2007 and 2012. Analysis showed that breastfeeding in parous women was protective against DCIS and LCIS, which is consistent with research on invasive breast cancer (IBC). Additionally, long-term use of HRT in post-menopausal women increased the risk of DCIS and LCIS, with a stronger association in LCIS, similar to the association with ILC. Contrary to findings with IBC, parity and the number of births were not protective against DCIS or LCIS, while oral contraceptives showed an unexpected protective effect. These findings suggest both similarities and differences in risk factors for DCIS and LCIS compared to IBC and that there may be justification for increased breast surveillance in post-menopausal women taking long-term HRT.

Funder

Breast Cancer Now, Cancer Research UK

Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust

King’s College London

Cancer Research UK

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3